Lyell Immunopharma (LYEL) Expected to Announce Quarterly Earnings on Wednesday

Lyell Immunopharma (NASDAQ:LYEL) is expected to announce its earnings results on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.

Lyell Immunopharma Stock Up 6.2 %

NASDAQ LYEL opened at $0.70 on Monday. The company has a market capitalization of $204.72 million, a price-to-earnings ratio of -0.89 and a beta of -0.35. Lyell Immunopharma has a twelve month low of $0.51 and a twelve month high of $3.26. The stock has a fifty day simple moving average of $0.61 and a 200 day simple moving average of $0.99.

Wall Street Analysts Forecast Growth

LYEL has been the subject of a number of recent research reports. HC Wainwright restated a “neutral” rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a report on Tuesday, November 12th. Bank of America downgraded Lyell Immunopharma from a “buy” rating to an “underperform” rating and decreased their price objective for the company from $6.00 to $1.00 in a report on Wednesday, October 30th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.